Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

ImmPACT Bio announces FDA clearance of its IND application for CD19/CD20 bispecific CAR-T cell therapy in multiple sclerosis

ImmPACT Bio USA Inc.a clinical-stage biopharmaceutical company developing a new generation of cellular therapies that have the potential to bring transformational benefits to patients, announced the United States Food and Drug Administration (FDA)...

Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis

disease. We are committed to a future without liver disease. About Gilead Sciences: Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating...

Aptar’s Nasal Unidose System will deliver neffy® (epinephrine nasal spray), the first FDA-approved needle-free treatment for Type I allergic reactions, including anaphylaxis

manufactured with strict quality controls intended to meet FDA’s guidelines for reliability. They offer biotech and pharmaceutical companies effective and reliable single or two-shot intranasal delivery for a variety of medicines including for...

Derm-Biome Pharmaceuticals to develop skincare treatment that promotes skin health and longevity

Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy aging, is excited to announce the development of a novel, science-backed skincare treatment aimed at targeting some of the root causes...

Spencer Trask & Co. launches Signal12 for Dry Eye Disease treatment, led by former Aerie executives, advancing Pro-ocular through trials

Signal12 as president and chief executive officer. Mitro is the former president and chief operating officer of Aerie Pharmaceuticals, where he grew annual sales to more than $100 million and facilitated a $770 million acquisition by Swiss eye-care...

Persist AI and Nivagen partner to develop AI-driven manufacturing for long-acting injectables

over weeks or months, improving patient adherence and outcomes. "We are excited to partner with Nivagen, a leading Pharmaceutical company with extensive experience and expertise in manufacturing and distributing pharmaceutical products. Together,...

Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma

Citius Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved LYMPHIR™ (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of r/r cutaneous T-cell lymphoma (CTCL) after at least one prior...

Axion BioSystems extends its agreement with Corning®, granting exclusive rights to distribute its award-winning cell counting device.

also includes impedance-based analyzers, automated imaging systems, and high-quality consumables used in academic, pharmaceutical, and biotech labs around the world. About Axion BioSystems: Axion BioSystems is a leading life sciences tools company...

Formosa licenses Clobetasol Propionate Ophthalmic Suspension to Apotex for ocular surgery relief

Taiwan-based Formosa Pharmaceuticals announced that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), for exclusive rights in Canada to the commercialization of clobetasol propionate ophthalmic suspension,...

Sensitech acquires Berlinger & Co. to expand life sciences cold chain solutions

company that specializes in innovative and customized solutions for monitoring temperature-sensitive goods in the pharmaceutical and life science, clinical trial and global health segments. Sensitech is part of Carrier Global Corporation global...

Jade Biosciences launches with $80 million to develop transformative autoimmune disease therapies

D.V.M., Ph.D., as Chief Scientific Officer, bringing more than 15 years of leadership experience across biotech and pharmaceutical industries to the organization. Dr. King previously served as Chief Scientific Officer of Chinook Therapeutics, a...

Eximia Research Network expands into Virginia by integrating Tidewater Clinical Research

research in specialized therapeutic areas, reinforcing their commitment to the community and the broader medical and pharmaceutical industry. "We are excited to welcome Tidewater Clinical Research to the Eximia network," says Grach. "Their...

Inoviv launches MasterKey™, a customizable platform for multiplexed protein assays

with Inoviv has been a productive collaboration," said Kristofer Fritz, PhD, Associate Professor in the Department of Pharmaceutical Sciences at the University of Colorado Anschutz Medical Campus. "Their expertise in identifying correlative...

Lipella Pharmaceuticals initiates Phase 2a trial for LP-310 in oral lichen planus, enrolling the first patients

Lipella Pharmaceuticals Inc. a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the enrollment of the first patients in its multi-center Phase 2a clinical trial evaluating LP-310 for the...

NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients

NewAmsterdam Pharma Company N.V a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”). For whom...

BerGenBio selects 2nd dose in Phase 2a STK11m Non-Small Cell Lung Cancer trial.

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced that the independent Data and Safety Monitoring Board (DSMB) for BerGenBio's Phase...

Innocan Pharma submits Investigational New Animal Drug application to FDA's Veterinary Center.

Innocan Pharma Corporation a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New...

Teva and Sanofi Announce Accelerated Anti-TL1A Phase 2b Program for Inflammatory Bowel Disease

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and Sanofi announced an update to the timing for the anti-TL1A, duvakitug (formerly known as TEV-’574/SAR447189) program investigating the human IgG1-λ2 monoclonal...

Transposon announces Phase 2 results for TPN-101 in treating C9orf72-related ALS and frontotemporal dementia

with FTD have a mean survival of nine years. About Transposon: Transposon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a platform of novel therapies for the treatment of neurodegenerative and aging-related diseases,...

Prolacta Bioscience Leads in Human Milk Science, Regularly Reviewing Health Claims with FDA

products, which have been evaluated in more than 30 peer-reviewed clinical studies. Operating the world's first pharmaceutical-grade human milk processing facilities, Prolacta maintains the industry's strictest quality and safety standards, with...